BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19417143)

  • 1. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor.
    Abouantoun TJ; MacDonald TJ
    Mol Cancer Ther; 2009 May; 8(5):1137-47. PubMed ID: 19417143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells.
    Abouantoun TJ; Castellino RC; MacDonald TJ
    J Neurooncol; 2011 Jan; 101(2):215-26. PubMed ID: 20524040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
    Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
    J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.
    Aoki M; Nabeshima K; Koga K; Hamasaki M; Suzumiya J; Tamura K; Iwasaki H
    Lab Invest; 2007 Aug; 87(8):767-79. PubMed ID: 17558420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
    Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
    Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
    Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells.
    Fred RG; Boddeti SK; Lundberg M; Welsh N
    Clin Sci (Lond); 2015 Jan; 128(1):17-28. PubMed ID: 24865476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells.
    Malavaki CJ; Roussidis AE; Gialeli C; Kletsas D; Tsegenidis T; Theocharis AD; Tzanakakis GN; Karamanos NK
    FEBS J; 2013 May; 280(10):2477-89. PubMed ID: 23374223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma.
    Katayama R; Huelsmeyer MK; Marr AK; Kurzman ID; Thamm DH; Vail DM
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):25-33. PubMed ID: 15108021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.
    Perros F; Montani D; Dorfmüller P; Durand-Gasselin I; Tcherakian C; Le Pavec J; Mazmanian M; Fadel E; Mussot S; Mercier O; Hervé P; Emilie D; Eddahibi S; Simonneau G; Souza R; Humbert M
    Am J Respir Crit Care Med; 2008 Jul; 178(1):81-8. PubMed ID: 18420966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
    Matei D; Chang DD; Jeng MH
    Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.
    van Steensel L; Paridaens D; Schrijver B; Dingjan GM; van Daele PL; van Hagen PM; van den Bosch WA; Drexhage HA; Hooijkaas H; Dik WA
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3091-8. PubMed ID: 19234339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
    McGary EC; Weber K; Mills L; Doucet M; Lewis V; Lev DC; Fidler IJ; Bar-Eli M
    Clin Cancer Res; 2002 Nov; 8(11):3584-91. PubMed ID: 12429650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
    Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
    J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
    Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
    Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
    J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
    J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
    Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells.
    Li L; Blumenthal DK; Masaki T; Terry CM; Cheung AK
    J Cell Biochem; 2006 Dec; 99(6):1553-63. PubMed ID: 16817200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.